Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease

Abstract

The effects of co-administration of quinpirole with benzazepine D1 dopamine (DA) agonists possessing full/supramaximal (SKF 80723 and SKF 82958), partial (SKF 38393 and SKF 75670) and no efficacies (SKF 83959) in stimulating adenylate cyclase (AC) were investigated in rodent and primate models of Parkinson's disease (PD). In rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle, co-administration of SKF 38393 (7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine), SKF 75670 (3-CH3 analogue), SKF 80723 (6-Br analogue), SKF 83959 (6-Cl, 3-CH3, 3′-CH3 analogue) and SKF 82958 (6-Cl, 3-C3H5 analogue) strongly potentiated the contralateral circling induced by quinpirole. In MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) treated common marmosets, administration of quinpirole alone increased locomotor activity and reversed motor deficits. Grooming and oral activity were unaltered. Co-administration of SKF 38393 and SKF 75670 inhibited the quinpirole-induced changes in locomotor activity and motor disability. The combined treatment of SKF 80723 or SKF 82958 with quinpirole had no overall effect on locomotor activity or motor disability. In contrast, SKF 83959 extended the duration of the quinpirole-induced increase in locomotor activity with corresponding decreases in motor disability. Co-administration of high doses of SKF 82958 and more especially SKF 83959 and SKF 80723, with quinpirole induced hyperexcitability and seizures. Oral activity and grooming were unaltered following the co-administration of benzazepine derivatives with quinpirole. The ability of some benzazepine D1 DA agonists to prolong the antiparkinsonian effects of quinpirole in the MPTP-treated marmoset may indicate a role for certain D1 DA agonists in the clinical treatment of PD. In general, the behavioural responses to the combined administration of benzazepines with quinpirole in the 6-OHDA lesioned rat and more especially the MPTP-treated marmoset failed to correlate with their ability to stimulate AC. These observations further implicate a behavioural role for D1 DA receptors not linked to AC.

This is a preview of subscription content, log in to check access.

References

  1. Arnt J (1985a) Behavioural stimulation is induced by separate dopamine D1 and D2 receptors in reserpine-pretreated but not in normal rats. Eur J Pharmacol 113:79–88

  2. Arnt J (1985b) Hyperactivity induced by stimulation of separate dopamine D1 and D2 receptors in rats with bilateral 6-OHDA lesions. Life Sci 37:717–723

  3. Arnt J, Hyttel J (1984) Differential inhibition by dopamine D1 and D2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol 102:349–354

  4. Arnt J, Bogeso KP, Hyttel J, Meier E (1988) Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol Toxicol 62:121–130

  5. Arnt J, Hyttel J, Sanchez C (1992) Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213:259–267

  6. Barone P, Davis TA, Braun AR, Chase TN (1986) Dopaminergic mechanisms and motor function: characterisation of D1 and D2 dopamine receptor interactions. Eur J Pharmacol 123:109–114

  7. Battaglia G, Norman AB, Hess EJ, Creese I (1986) Functional recovery of D1 dopamine receptor mediated stimulation of rat striatal adenylate cyclase activity following irreversible modification byN-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): evidence for spare receptors. Neurosci Lett 69:290–295

  8. Bedard PJ, Boucher R (1989) Effect of D1 receptor stimulation in normal and MPTP monkeys. Neurosci Lett 104:223–228

  9. Bertorello AM, Hopfield JF, Aperia A, Greengard P (1990) Inhibition by dopamine of (Na+/K+) ATPase activity in neostriatal neurones through D1 and D2 dopamine receptor synergism. Nature 347:386–388

  10. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD (1990) Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 40:927–933

  11. Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN (1987) Selective D1 dopamine agonist treatment of Parkinson's disease. J Neural Transm 68:41–50

  12. Close SP, Marriott AS, Pay S (1985) Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Br J Pharmacol 85:320–322

  13. Close SP, Elliott PJ, Hayes AG, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology 102:295–300

  14. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1991) Drugs acting at D1 and D2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology 103:503–512

  15. Dall'Olio R, Gandolfi O, Vaccheri A, Roncada P, Montanaro N (1988) Changes in behavioural responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats. Psychopharmacology 95:381–385

  16. Daly SA, Waddington JL (1992) D1 dopamine receptors and the topography of unconditioned motor behaviour: studies with the selective, “full efficacy” benzazepine D1 agonist SKF 83189. J Psychopharmacol 6:50–60

  17. DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bednarz L, Bhatt R, Curzon P, Gomez E, Kang CH, Stitts J, Kebabian JW (1991) A68930: a potent agonist selective for the dopamine D1 receptor. Eur J Pharmacol 199:209–219

  18. Domino EF, Sheng J (1993) Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 265:1387–1391

  19. Downes RP, Waddington JL (1993) Grooming and vacuous chewing induced by SKF 83959 and agonist of dopamine “D1 like” receptors that inhibits dopamine sensitive adenylyl cyclase. Eur J Pharmacol 234:135–136

  20. Emre M, Rinne UK, Rascol A, Lees A, Agid Y, Lataste X (1992) Effects of a selective partial D1 agonist, CY 208–243, in de novo patients with Parkinson's disease. Mov Disord 7:239–243

  21. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD (1994) The differential antiparkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated marmoset. Psychopharmacology

  22. Gower AJ, Marriott A (1982) Pharmacological evidence for the subclassification of central dopamine receptors in the rat. Br J Pharmacol 77:185–194

  23. Hess EJ, Battaglia G, Norman AB, Creese (1987) Differential modification of striatal D1 dopamine receptors and effector moieties byN-ethoxycarbonyl-2-thoxy-1,2-dihydroquinoline in vivo and in vitro. J Pharmacol Exp Ther 31:50–57

  24. Itoh Y, Beaulieu M, Kebabian J (1984) The chemical basis for the blockade of the D1 dopamine receptor by SCH 23390. Eur J Pharmacol 100:119–122

  25. Izenwasser S, Katz J (1993) Differential efficacies of dopamine D1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur J Pharmacol - [Mol Pharmacol] 246:39–44

  26. Johansen PA, Hu X-T, White FJ (1991) Relationship between D1 dopamine receptors, adenylate cyclase and the electrophysiological responses of rat nucleus accumbens neurones. J Neural Transm 86:97–113

  27. Johansson P, Levin E, Gunne L, Ellison G (1987) Opposite effects of D1 and D2 agonist on oral movements in rats. Eur J Pharmacol 134:83–88

  28. Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, Schoenleber R, Williams M (1992) A77636: A potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203–209

  29. Loschmann PA, Smith LA, Lange KW, Jaehnig P, Jenner P, Marsden CD (1991) Motor activity following the administration of selective D1 and D2 dopaminergic drugs to normal common marmosets. Psychopharmacology 105:303–309

  30. Loschmann PA, Smith LA, Lange KW, Jaehnig P, Jenner P, Marsden CD (1992) Motor activity following the administration of selective D1 and D2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 109:49–56

  31. Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB (1989) Dihydrexidine, a novel selective high potency full dopamine D1 receptor agonist. Eur J Pharmacol 166:111–113

  32. Madras BK, Fahey MA, Canfield DR, Spealman RD (1988) D1 and D2 dopamine receptors in caudate-putamen of non-human primates (Macaca fascicularis). J Neurochem 51:934–943

  33. Mahan LC, Burch RM, Monsma FJ, Sibley DR (1990) Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilisation inXenopus oocytes. Proc Natl Acad Sci 87:2196–2200

  34. Mailman RB, Schulz DW, Kilts CD, Lewis MH, Rollema H, Wyrick S (1986) The multiplicity of the D1 dopamine receptor. Neurobiology of central D1 dopamine receptors. In: Breese GR, Creese I (eds) Adv Exp Med Biol 204:53–72

  35. Markstein R, Seiler NP, Vigouret JM, Urwyler S, Enz A, Dixon K (1988) Pharmacological properties of CY 208–243, and normal D1 agonists, In Sandler M. ed. Proceedings of XIth international catecholamine symposium Part B: Central aspects. Alan R Liss, New York, pp 59–64

  36. Mashurano M, Waddington JL (1986) Stereotyped behaviour in response to the selective D2 dopamine agonist RU 24213 is enhanced by pretreatment with the selective D1 agonist SK&F 38393. Neuropharmacology 25:947–949

  37. Murray AM, Waddington JL (1989) The induction of grooming and vacuous chewing by a series of selective D1 dopamine agonists: two directions of D1:D2 interaction. Eur J Pharmacol 160: 377–384

  38. Nomoto M, Jenner P, Marsden CD (1985) The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393 reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 57:37–41

  39. Nomoto M, Jenner P, Marsden CD (1988) The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset. Neurosci Lett 93:275–280

  40. O'Boyle KM, Waddington JL (1987) [3H]-SCH 23390 binding to human putamen D1 dopamine receptors: stereochemical and structure-affinity relationships among 1-phenyl-1H-3-benzazepine derivatives as a guide to D1 receptor topography. J Neurochem 48:1039–1042

  41. O'Boyle KM, Gaitanopoulos DE, Brenner M, Waddington JL (1989) Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor. Neuropharmacology 28:401–405

  42. Peacock L, Lublin H, Gerlach J (1990) The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186:49–59

  43. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A stereotaxic atlas of the rat brain. Plenum Press, London

  44. Pifl C, Reither H, Hornykiewicz O (1991) Lower efficacy of the dopamine D1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur J Pharmacol 202:273–276

  45. Piomelli D, Pilon C, Giros B, Sokoloff P, Martes M-P, Schwartz J-C (1991) Dopamine activation of the arachidonic acid cascade as a basis for D1/D2 receptor synergism. Nature 353:164–167

  46. Robertson GS, Robertson HA (1986) Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats. Brain Res 384:387–390

  47. Rosengarten H, Schweitzer JW, Friedhoff AJ (1986) Selective dopamine D2 receptor reduction enhances a D1 mediated oral dyskinesia in rats. Life Sci 39:29–35

  48. Rouillard C, Bedard PJ (1988) Specific D1 and D2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model in the rat. Neuropharmacology 27:1257–1264

  49. Rouillard C, Bedard PJ, Di Paolo T (1990) Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. Eur J Pharmacol 185:209–215

  50. Rupniak NMJ, Boyce S, Steventon M, Iversen SD (1992) Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates. Clin Neuropharmacol 15:307–309

  51. Schoors DF, Vauquelin GP, Vos HD, Smets G, Velkeniers B, Vanhaelst L, Dupont AG (1991) Identification of a D1 dopamine receptor, not linked to adenylate cyclase, on lactotroph cells. Br J Pharmacol 103:1928–1934

  52. Setler PE, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50:419–430

  53. Sibley DR, Monsma FJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69

  54. Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990) Molecular cloning and characterisation of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 34:146–151

  55. Sunahara RK, Guan H-C, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HHM, Niznik HB (1991) Cloning of the gene for a human dopamine D5 receptor with high affinity for dopamine than D1. Nature 350:614–619

  56. Undie AS, Friedman E (1990) Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J Pharmacol Exp Ther 253:987–992

  57. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal system. Brain Res 14:461–471.

  58. Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB (1993) Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF 38393) agonists in primates vs. rodents. Eur J Pharmacol 24:165–172

  59. Weinstock J, Hieble JP, Wilson JW (1985) The chemistry and pharmacology of 3-benzazepine derivatives. Drugs Future 10:645–696

  60. Weinstock J, Ladd DL, Wilson JW, Brush CK, Yim NCF, Gallagher G, McCarthy ME, Silvestri J, Sarau HM, Flaim KE, Ackerman DM, Setler PE, Tobia AJ, Hahn RA (1986) Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam. J Med Chem 29:2315–2325

Download references

Author information

Correspondence to Peter Jenner.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gnanalingham, K.K., Jenner, P., Hunter, A.J. et al. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology 117, 287–297 (1995). https://doi.org/10.1007/BF02246103

Download citation

Key words

  • D1 dopamine agonists
  • Quinpirole
  • MPTP Marmoset
  • Rat
  • 6-Hydroxydopamine
  • Behaviour